A randomized study of Folfox was presented in the 2010 ASCO meeting. When compared with doxorubicin after 266 events, the FOLFOX4 regimen significantly improved median progression-free survival from 1.77 to 2.93 months (P = .0002) in the EACH trial. Overall survival also improved from 4.97 to 6.40 months, although the difference failed to reach statistical significance at that point (P = .0695), At taht meeting, Dr. Qin presented updated efficacy results after 305 events that left survival rates virtually unchanged, but pushed overall survival to statistical significance (4.90 vs. 6.47 months), but pushed overall survival to statistical significance at a P value of .0425).
Response rates (complete and partial responses) by RECIST (Response Evaluation Criteria in Solid Tumors) were 8.7% for FOLFOX4 and 2.7% for doxorubicin (P = .0142). Disease control rates (complete and partial responses and stable disease) were 53% for FOLFOX4 vs. 32% for doxorubicin (P less than .0001).
While these are preliminary results and not truly peer-reviewed, they represent the first survival advantage reproted for HCC for any chemo regimen.
V. Boige et al, Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial Br J Cancer 97, 862-867, 207
Comments